Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan

Contributed by: Business Wire

Logo

Tags

Cardiology

Pharmaceutical

Oncology

General Health

Health

FDA

Infectious Diseases

Clinical Trials

More Like This

Curatis discloses Corticorelin as active substance of C-PTBE-01

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3

Curatis will apply for a Biologic License for C-PTBE-01 in the USA - this will significantly increase the duration of market protection in the USA in the event of approval

Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01

Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-01

Curatis on track: submission of orphan drug designation application in the US for lead product candidate

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues